Breaking Down SG&A Expenses: Johnson & Johnson vs TG Therapeutics, Inc.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, understanding the financial health of a company is crucial. This chart provides a fascinating comparison of Selling, General, and Administrative (SG&A) expenses between two industry players: Johnson & Johnson and TG Therapeutics, Inc., from 2014 to 2023.

Johnson & Johnson, a titan in the healthcare sector, consistently reported SG&A expenses in the range of $19 billion to $22 billion annually. Notably, their expenses peaked in 2018, reflecting a strategic investment phase. However, a slight decline was observed in 2022, indicating a possible shift in operational strategy.

On the other hand, TG Therapeutics, a smaller biotech firm, showed a different trajectory. Their SG&A expenses grew significantly, from approximately $12 million in 2016 to over $120 million in 2023, marking a tenfold increase. This surge highlights their aggressive expansion and development efforts.

This comparison underscores the diverse financial strategies employed by established giants and emerging innovators in the pharmaceutical industry.